340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

National Newspaper Ad Hits Genentech’s Specialty-Drug Switch

Open letter in The New York Times calls for reversal of "ill-advised" change 

November 24, 2014—A leading hospital group purchasing organization and 16 prominent health care institutions asked Genentech in an open letter in The New York Times yesterday to reverse its "ill-advised decision" to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the more expensive specialty distribution channel. … [Read more...]

Study: Hospital Cancer Clinics See Four Times More Poor Patients as Private Clinics

Patients are sicker and have more complex conditions 

November 21, 2014—Cancer patients treated in hospital outpatient departments are almost four times more likely than those treated in physician offices to be uninsured or covered by Medicaid, a new study commissioned by the American Hospital Association shows. These patients also tend to be sicker and come from lower-income communities. … [Read more...]

Briefing Schedule Set for Second 340B Orphan Drug Lawsuit

Judge who heard first case will hear the follow-up 

November 20, 2014—Final briefs in the drug industry's second lawsuit over the 340B orphan drug exclusion will be due in late March 2015, under a federal district court scheduling order filed this week. … [Read more...]

27 Senators Urge President to Protect Critical Access Hospitals

Don't repeat proposals from prior budgets in FY 2016 request, they ask 

November 20, 2014—A bipartisan group of 27 U.S. Senators has asked President Obama not to weaken critical access hospitals in his forthcoming fiscal year 2016 budget request to Congress. … [Read more...]

PhRMA Pushes to Reopen 340B Statute on Capitol Hill

Hospitals say legislative changes could put program in jeopardy 

The drug industry has announced it wants Congress to reopen the original 340B law to give the Health Resources and Services Administration additional rule- making authority to regulate the program. … [Read more...]

Goodbye, 340B Mega-Reg. Hello, 340B Guidance

Welcome back, proposed rules on manufacturer sanctions and dispute resolution 

November 14, 2014—The Health Resources and Services Administration said for the record this morning that, in 2015, it  "plans to issue a proposed guidance for notice and comment that will address key policy issues raised by various stakeholders committed to the integrity of the 340B program."   … [Read more...]

Congress Asked to Investigate Genentech’s Specialty-Drug Switch

10 major academic medical centers seek expedited review 

November 14, 2014—Ten of the nation's leading academic medical centers have asked Congress to investigate Genentech's decision to move the world’s three top-selling cancer drugs into the more expensive specialty distribution channel. … [Read more...]

« Previous Page
Next Page »

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health